Cargando…
Effects of long-term cysteamine treatment in patients with cystinosis
Cystinosis is a rare autosomal-recessive lysosomal storage disease with high morbidity and mortality. It is caused by mutations in the CTNS gene that encodes the cystine transporter, cystinosin, which leads to lysosomal cystine accumulation. Patients with infantile nephropathic cystinosis, the most...
Autores principales: | Ariceta, Gema, Giordano, Vincenzo, Santos, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394685/ https://www.ncbi.nlm.nih.gov/pubmed/29260317 http://dx.doi.org/10.1007/s00467-017-3856-4 |
Ejemplares similares
-
Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride
por: Liang, Hong, et al.
Publicado: (2021) -
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
por: Klank, Sabrina, et al.
Publicado: (2023) -
Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults
por: Ariceta, Gema, et al.
Publicado: (2015) -
Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
por: Bouazza, Naïm, et al.
Publicado: (2011) -
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023)